Neridronate Sodium

Neridronate sodium was approved on Jan 1, 2002 in Italy. It was developed and marketed as Nerixia® by Abiogen in Italy.

Neridronate is a new amino bisphosphonate. It is indicated to treat osteogenesis imperfecta and paget's disease of bone.

Nerixia® is available as injection solution for intravenous use, containing 25 or 100 mg of Neridronate sodium. The indicative posology is of 2 mg/kg body weight every 3 months.

General Information

Update Date:2015-09-07

Drug Name:
Neridronate Sodium
Research Code:
Trade Name:
Nerixia®
MOA:
Bisphosphonate
Indication:
Osteogenesis imperfecta; Paget's disease
Status:
Approved
Company:
Abiogen (Originator)
Sales:
ATC Code:
M05BA
Approved Countries or Area

Update Date:2015-07-29

Approval Date Approval Type Trade Name Indication Dosage Form Strength Company Review Classification
2002-01-01 Marketing approval Nerixia Osteogenesis imperfecta,Paget's disease Injection, Solution 25 mg/100 mg Abiogen
Chemical Structure

Update Date:2015-08-27

Molecular Weight 299.13
Formula C6H16NO7P2 • Na
CAS No. 79778-41-9 (Neridronic Acid);
80729-79-9 (Neridronate Sodium);
Chemical Name 6-Amino-1-hydroxy-1,1-hexanediphosphonic Acid Monosodium Salt
Neridronic Acid (Free Acid/Base)Parameters:
MW HD HA FRB* PSA* cLogP*
277.15 7 8 9 181 -0.397±0.610
*:Calculated by ACD/Labs software V11.02.
Synthesis & Impurities

Update Date:2015-10-09

Impurity database is being updated!